AAAAAA

   
Results: 1-11 |
Results: 11
Addition of rapamycin to cyclosporine-prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA antibody
Authors: Kerman, RH Katz, SM Van Buren, CT Garcia, C Kahan, BD
Citation: Rh. Kerman et al., Addition of rapamycin to cyclosporine-prednisone based immunosuppression reduces the clinical risk of pretransplant anti-HLA antibody, TRANSPLAN P, 33(1-2), 2001, pp. 401-401
Posttransplant immune monitoring of anti-HLA antibody
Authors: Kerman, RH Katz, SM Van Buren, CT Ruth, J McKissick, E Rasmussen, S Kahan, BD
Citation: Rh. Kerman et al., Posttransplant immune monitoring of anti-HLA antibody, TRANSPLAN P, 33(1-2), 2001, pp. 402-402
Impact of sirolimus on renal transplant outcomes in African Americans
Authors: Podder, H Podbielski, J Hussein, I Katz, SM Van Buren, CT Kahan, BD
Citation: H. Podder et al., Impact of sirolimus on renal transplant outcomes in African Americans, TRANSPLAN P, 33(1-2), 2001, pp. 1226-1226
Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes
Authors: Kahan, BD Napoli, KL Podbielski, J Hussein, I Katz, SH Van Buren, CT
Citation: Bd. Kahan et al., Therapeutic drug monitoring of sirolimus for optimal renal transplant outcomes, TRANSPLAN P, 33(1-2), 2001, pp. 1278-1278
Guillain-Barre syndrome after solid organ transplantation
Authors: El-Sabrout, R Radovancevic, B Ankoma-Sey, V Van Buren, CT
Citation: R. El-sabrout et al., Guillain-Barre syndrome after solid organ transplantation, TRANSPLANT, 71(9), 2001, pp. 1311-1316
Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs
Authors: Kahan, BD Welsh, M Urbauer, DL Mosheim, MB Beusterien, KM Wood, MR Schoenberg, LP Dicesare, J Katz, SM Van Buren, CT
Citation: Bd. Kahan et al., Low intraindividual variability of cyclosporin A exposure reduces chronic rejection incidence and health care costs, J AM S NEPH, 11(6), 2000, pp. 1122-1131
Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity
Authors: Kahan, BD Napoli, KL Kelly, PA Podbielski, J Hussein, I Urbauer, DL Katz, SH Van Buren, CT
Citation: Bd. Kahan et al., Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity, CLIN TRANSP, 14(2), 2000, pp. 97-109
A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients
Authors: Kahan, BD Wong, RL Carter, C Katz, SH Von Fellenberg, J Van Buren, CT Appel-Dingemanse, S
Citation: Bd. Kahan et al., A phase I study of a 4-week course of SDZ-RAD (RAD) in quiescent cyclosporine-prednisone-treated renal transplant recipients, TRANSPLANT, 68(8), 1999, pp. 1100-1106
Flow cytometry-detected IgG is not a contraindication to renal transplantation - IgM may be beneficial to outcome
Authors: Kerman, RH Susskind, B Buyse, I Pryzbylowski, P Ruth, J Warnell, S Gruber, SA Katz, S Van Buren, CT Kahan, BD
Citation: Rh. Kerman et al., Flow cytometry-detected IgG is not a contraindication to renal transplantation - IgM may be beneficial to outcome, TRANSPLANT, 68(12), 1999, pp. 1855-1858
Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch?
Authors: Kerman, RH Susskind, B Ruth, J Katz, S Van Buren, CT Kahan, BD
Citation: Rh. Kerman et al., Can an immunologically, nonreactive potential allograft recipient undergo transplantation without a donor-specific crossmatch?, TRANSPLANT, 66(12), 1998, pp. 1833-1834
Financial compensation for cadaver organ donation: Good idea or anathema?
Authors: Caplan, AL Van Buren, CT Tilney, NL
Citation: Al. Caplan et al., Financial compensation for cadaver organ donation: Good idea or anathema?, ETHICS OF ORGAN TRANSPLANTS: THE CURRENT DEBATE, 1998, pp. 219-223
Risultati: 1-11 |